By Denny Jacob
Shares of Esperion Therapeutics jumped 11% in premarket trading after fourth-quarter revenue more than doubled from the prior-year period.
Shares were trading around $1.76. The stock is down 34% over the last year.
The pharmaceutical company recorded revenue of $69.1 million, compared with $32.3 million a year earlier. Analysts polled by FactSet had expected $61.6 million.
"We expect to drive further revenue growth and reach operating profitability through durable growth of our bempedoic acid products in the U.S. and Europe, and through global expansion," said Chief Executive Sheldon Koenig.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 04, 2025 06:26 ET (11:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.